IPO Guru
EquiVision

EquiVision

🏅 Ranked #30 on IPO Guru
SEBI Registered RA · INH000021377

EquiVision, the research division of Beacon Capital Advisors Pvt. Ltd., is a results-driven equity research and investor relations firm focused on India's SME and mid-cap landscape. With a commitment to integrity, innovation, and client-centricity, EquiVision delivers customized, actionable insights that guide businesses and investors through every stage of their growth journey — from pre-IPO strategy to post-listing market positioning.

Visit Website 17 Mainboard 67 SME

Total Reviews

84

All time

Apply Rate

74%

of all calls

Win Rate

47%

Apply calls with +ve listing

Avg Listing Gain

+6.1%

on apply/may apply calls

Avg Total Gain

+20.3%

on apply/may apply calls

53 Score / 100
⚠️ Mixed Record

Performance Dashboard

Performance is mixed; some calls worked, some did not.

Based on 80 reviews in the last 12 months.

How is this calculated?

Accuracy

83%

Return Quality

89%

Consistency

38%

Horizon

59%

⚠️ Disclaimer: Past results are not guaranteed for future. This score reflects the last 1 year only. Use for research purposes only.

Verdict Breakdown (All Time)

Apply 47 (59%)
May Apply 15 (19%)
Neutral 4 (5%)
Avoid 14 (18%)
Accretion Nutraveda

🏆 Best Call

Accretion Nutraveda

Verdict: Apply

+48.1%

Listing gain

Y

📉 Worst Call

Yajur Fibres

Verdict: Apply

-20.0%

Listing gain

Review History

Track record of EquiVision

IPO Name Verdict Total Gain Report
Hexagon Nutrition
Hexagon Nutrition
May Apply +45.6% PDF
UHM Vacation
UHM Vacation
May Apply -79.0% PDF
CMR Green Technologies
CMR Green Technologies
May Apply +13.6% PDF
Yaashvi Jewellers
Yaashvi Jewellers
May Apply -13.3% PDF
M R Maniveni Foods
M R Maniveni Foods
Apply -41.8% PDF
Bio Medica Laboratories
Bio Medica Laboratories
Apply -0.2% PDF
Autofurnish
Autofurnish
May Apply +43.6% PDF
Q-Line Biotech
Q-Line Biotech
May Apply +47.4% PDF
Goldline Pharmaceutical
Goldline Pharmaceutical
May Apply -11.3% PDF
RFBL Flexi Pack
RFBL Flexi Pack
Avoid +84.8% PDF
Simca Advertising
Simca Advertising
Apply +11.1% PDF
Bagmane Prime Office REIT
Bagmane Prime Office REIT
Not Rated +4.6% PDF
Recode Studios
Recode Studios
Apply +38.4% PDF
Value 360 Communications
Value 360 Communications
May Apply -18.4% PDF
OnEMI Technology Solutions (KISSHT)
OnEMI Technology Solutions (KISSHT)
Apply +98.9% PDF
Amba Auto Sales & Services
Amba Auto Sales & Services
Avoid -40.8% PDF
Adisoft Technologies
Adisoft Technologies
Apply +6.7% PDF
Mehul Telecom
Mehul Telecom
May Apply -4.1% PDF
Safety Controls & Devices
Safety Controls & Devices
Avoid -13.3% PDF
Emiac Technologies
Emiac Technologies
May Apply -3.4% PDF

Frequently Asked Questions

Is EquiVision SEBI registered?

Yes, EquiVision is a SEBI registered Research Analyst (Registration No. INH000021377). SEBI registration means the analyst is regulated by the Securities and Exchange Board of India and authorised to publish investment research.

How many IPO reviews has EquiVision given?

EquiVision has reviewed 84 IPOs in total, covering 17 Mainboard and 67 SME IPOs. The apply rate across all calls is 74%.

What is EquiVision's IPO recommendation win rate?

EquiVision has a 47% win rate — 47% of their Apply calls resulted in a positive listing gain on the NSE/BSE. The average listing gain on Apply calls is +6.1%.

What is EquiVision's performance score on IPO Guru?

EquiVision holds a performance score of 53/100 (⚠️ Mixed Record), ranking #30 among all analysts tracked on IPO Guru. The score is based on accuracy, return quality, consistency, and horizon over the last 12 months.

Where can I read EquiVision's IPO recommendations?

All IPO reviews by EquiVision are listed on this page. You can filter by the last 12 months or all-time, and view the verdict (Apply / May Apply / Neutral / Avoid) alongside the actual listing and current gains for each IPO.